Study summary

Immunotherapy alone cleared every dMMR rectal cancer that finished treatment

Dostarlimab without surgery (MSK trial) · 117 people, phase 2 · Published June 2025, New England Journal of Medicine

92%free of recurrence at 2 years

What was tested

Six months of dostarlimab, a PD-1 immunotherapy, before planned surgery for stage I to III dMMR tumors. People whose tumor disappeared could skip surgery. No comparison group.

What they found

What it means

For dMMR rectal cancer, immunotherapy may replace surgery, radiation and chemotherapy.

N Engl J Med, via PubMed ↗ Trial record NCT04165772 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.